Well reasoned IMHO:
@AndrewCaravello
$NWBO 🎯 The Push Is for DCVax. Not mRNA. The Backlog Confirms It.
Let’s be absolutely clear. Statutory Instrument 2025 No. 87 was not created for mRNA. It was crafted to remove a very specific legal barrier that stood in the way of one last remaining product. A therapy that is personalized, autologous, and manufactured for each patient using living immune cells. A therapy that already exists under the UK Specials program. That therapy is DCVax-L from Northwest Biotherapeutics.
And this is not speculation. It is already confirmed that the MHRA has cleared the entire backlog of applications related to this statutory instrument. All other eligible products have received decisions. Only one remains. That is DCVax.
📜 SI 2025 No. 87 Was Written for One Product
The law amended existing UK regulations to enable full marketing authorization of advanced therapy medicinal products that had previously been limited to Specials access. This change specifically addressed the bottleneck for individualized, patient-specific therapies. DCVax-L is the only commercial-stage product that fit every aspect of this legal framework.
No other company had a therapy pending under these exact conditions. No other product required both autologous design and a statutory change to convert from Specials to full licensure. DCVax is the only one.
🚫 This Was Never About mRNA
mRNA cancer vaccines from BioNTech and Moderna are being pushed through the UK’s Cancer Vaccine Launchpad and NHS partnerships using synthetic, off-the-shelf manufacturing. They never needed this law. Their trials have already started. Their approval paths already exist. There was no legal gap to close.
If this were about mRNA, there would have been multiple applications affected. There were none. The statutory update was for one remaining therapy that did not have a clear licensing path under existing frameworks. That therapy is DCVax.
🔐 Regulatory Timing Confirms It
The timeline is precise. SI 2025 No. 87 became effective on June 17. Its full enforcement begins on July 23. This created a legal corridor, a window designed to finalize one outstanding application under the new rules. Every other product has moved. Nothing else is waiting. The only active, affected, and qualifying application is DCVax.
🧠 Final Word
The law was written for DCVax.
The application backlog is cleared except for DCVax.
The manufacturing system that matches this framework is Flaskworks.
The clinical use already happening under Specials is DCVax.
And the only product ready for full licensure under this exact model is DCVax.
While politicians and media focus on mRNA, the law speaks clearly. The UK regulatory system just made space for one therapy to cross the threshold. DCVax is not coming later. It is next.
Market Data 
Markets 
AI
